A facility for the manufacture of vaccines using Novavax's virus-like particle technology is currently undergoing validation outside Ahmadabad, India. The plant has the capacity to produce 60 million doses per year.
CPL Biologicals, a joint venture Cadila Pharmaceuticals and Novavax, announced completion of construction. The JV plans to produce seasonal and pandemic flu vaccines.
Cadila says the VLP recombinant technology will permit fast vaccine-production response for pandemics. But CPL is still lacking Indian regulatory approval to conduct clinical trials in-country for VLP-based swine flu vaccine. Meanwhile, Indian drugmakers have recently come online as producers of egg-based flu vaccines.
- here's the article